KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pfizer (PFE) Other Gross PP&E Adjustments (2016 - 2025)

Pfizer has reported Other Gross PP&E Adjustments over the past 17 years, most recently at $34.5 billion for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments rose 5.84% to $34.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $34.5 billion through Dec 2025, up 5.84% year-over-year, with the annual reading at $34.5 billion for FY2025, 5.84% up from the prior year.
  • Other Gross PP&E Adjustments was $34.5 billion for Q4 2025 at Pfizer, up from $32.6 billion in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $34.5 billion in Q4 2025 and troughed at $27.1 billion in Q4 2021.
  • The 5-year median for Other Gross PP&E Adjustments is $32.1 billion (2023), against an average of $30.9 billion.
  • Year-over-year, Other Gross PP&E Adjustments increased 0.36% in 2021 and then grew 12.71% in 2023.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $27.1 billion in 2021, then grew by 4.9% to $28.4 billion in 2022, then rose by 12.71% to $32.1 billion in 2023, then grew by 1.64% to $32.6 billion in 2024, then increased by 5.84% to $34.5 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Other Gross PP&E Adjustments are $34.5 billion (Q4 2025), $32.6 billion (Q4 2024), and $32.1 billion (Q4 2023).